ABSTRACT
Cervical cancer (CC) represents a major global health issue, particularly impacting women from resource constrained regions worldwide. Treatment refractoriness to standard chemo-radiotherapy has identified cancer stem cells as critical coordinators behind the biological mechanisms of resistance, contributing to CC recurrence. In this work, we evaluated differential gene expression in cervical cancer stem-like cells (CCSC) as biomarkers related to intrinsic chemoradioresistance in CC. A total of 31 patients with locally advanced CC and referred to Mario Penna Institute (Belo Horizonte, Brazil) from August 2017 to May 2018 were recruited for the study. Fluorescence-activated cell sorting (FACS) was used to enrich CD34+/CD45-CCSC from tumor biopsies. Transcriptome was performed using ultra-low input RNA sequencing and differentially expressed genes (DEGs) using Log2 fold differences and adjusted p value < 0.05 were determined. A panel of biomarkers was selected using the rank-based AUC (Area Under the ROC Curve) and pAUC (partial AUC) measurements for diagnostic sensitivity and specificity. The analysis showed 1062 DEGs comparing between the Non-Responder (n=10) and Responder (n=21) groups to chemoradiotherapy. Overlapping of the 20 highest AUC and pAUC values revealed five transcripts potentially implicated in innate chemoresistance (ILF2, SNX2, COPZ1, AC016722.1 and AL360175.1). This study identifies DEG signatures that serve as potential biomarkers in CC prognosis and treatment outcome, as well as identifies potential alternative targets for cancer therapy.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Ministry of Health (Pronon - Grant number: NUP:25000.159953/2014-18) and the Minas Gerais State Research Agency (FAPEMIG - Grant number: TCT 19.011-13 - RT 00003-13). KJG is a CNPq Research Fellow.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Ethics Committee at Instituto Mario Penna, Belo Horizonte, MG, which is registered with the Brazilian national ethics authority (CONEP). The study was approved (approval number: 1.583.784) for performing the prospective study with each patient signing a written informed consent before the initiation of any procedure related to the study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Datasets used in this study will be available upon reasonable request to the corresponding authors upon IRB review and approval for release of data to third parties.
List of abbreviations (in alphabetical order)
- CC
- cervical cancer
- CSC
- cancer stem cell
- CCSC
- cervical cancer stem-like cells
- CCNSC
- Cancer non-stem cell
- FACS
- Fluorescence-activated cell sorting
- DEG
- Differentially expressed gene
- Log2FC
- Log2 fold change
- AUC
- Area under the curve
- pAUC
- partial area under the curve
- ROC
- Receiver operating characteristic curve
- GLOBOCAN
- Global Cancer Observatory
- HPV
- Human papillomavirus
- RNA
- Ribonucleotide
- SCC
- Squamous cell carcinoma
- ADC
- Adenocarcinoma
- FIGO
- International Federation of Gynecology and Obstetrics
- FDR
- False Discovery Rate
- NR
- Non-Responder
- R
- Responder
- LR
- Logistic Regression